The effects of lemborexant on insomnia-related fatigue: a plain language summary

IF 0.6 Q4 CLINICAL NEUROLOGY
C. Chepke, Rakesh Jain, Russell Rosenberg, M. Moline, J. Yardley, K. Pinner, Dinesh Kumar, Carlos Perdomo, G. Filippov, N. Atkins, Manoj Malhotra
{"title":"The effects of lemborexant on insomnia-related fatigue: a plain language summary","authors":"C. Chepke, Rakesh Jain, Russell Rosenberg, M. Moline, J. Yardley, K. Pinner, Dinesh Kumar, Carlos Perdomo, G. Filippov, N. Atkins, Manoj Malhotra","doi":"10.2217/fnl-2023-0018","DOIUrl":null,"url":null,"abstract":"This is a summary of an article originally published in the journal Postgraduate Medicine. Lemborexant is a type of medication called a dual orexin receptor antagonist (often abbreviated to DORA) that is approved for treating people with insomnia, a sleep disorder in which people have trouble falling asleep, staying asleep or both. Two studies, one called SUNRISE-1 (Study 304), which lasted one month, and SUNRISE-2 (Study 303), which lasted 12 months, looked at the effects of lemborexant on sleep compared to placebo in people with insomnia. People with insomnia often experience fatigue (or tiredness) during the daytime, which affects their daily lives and health, and often have other conditions which can also cause fatigue. This summary reports an analysis that looked at whether lemborexant improves fatigue during the daytime as well as nighttime symptoms of insomnia in all participants and in participants with clinically significant fatigue before treatment. In both studies, participants completed a questionnaire, called the Fatigue Severity Scale, that measured how significant their fatigue was. The researchers looked at the change in fatigue over time in participants treated with lemborexant compared with those given placebo. They also looked at the change in a group of participants who reported clinically important levels of fatigue at the beginning of the study. People in these studies also completed diaries about how long it took them to fall asleep and how long they slept. The researchers compared improvements in fatigue with changes in how participants slept over time. Overall, lemborexant reduced daytime fatigue compared with placebo in all study participants. It also reduced daytime fatigue in the smaller group of participants who had clinically significant fatigue at the beginning of the study. The reductions in fatigue seen with lemborexant remained during 1 year of treatment. There was also a relationship between reduced fatigue, falling asleep faster and not waking up as much. Researchers concluded that in addition to improving sleep in people with insomnia, lemborexant can reduce daytime fatigue.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"70 4","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fnl-2023-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This is a summary of an article originally published in the journal Postgraduate Medicine. Lemborexant is a type of medication called a dual orexin receptor antagonist (often abbreviated to DORA) that is approved for treating people with insomnia, a sleep disorder in which people have trouble falling asleep, staying asleep or both. Two studies, one called SUNRISE-1 (Study 304), which lasted one month, and SUNRISE-2 (Study 303), which lasted 12 months, looked at the effects of lemborexant on sleep compared to placebo in people with insomnia. People with insomnia often experience fatigue (or tiredness) during the daytime, which affects their daily lives and health, and often have other conditions which can also cause fatigue. This summary reports an analysis that looked at whether lemborexant improves fatigue during the daytime as well as nighttime symptoms of insomnia in all participants and in participants with clinically significant fatigue before treatment. In both studies, participants completed a questionnaire, called the Fatigue Severity Scale, that measured how significant their fatigue was. The researchers looked at the change in fatigue over time in participants treated with lemborexant compared with those given placebo. They also looked at the change in a group of participants who reported clinically important levels of fatigue at the beginning of the study. People in these studies also completed diaries about how long it took them to fall asleep and how long they slept. The researchers compared improvements in fatigue with changes in how participants slept over time. Overall, lemborexant reduced daytime fatigue compared with placebo in all study participants. It also reduced daytime fatigue in the smaller group of participants who had clinically significant fatigue at the beginning of the study. The reductions in fatigue seen with lemborexant remained during 1 year of treatment. There was also a relationship between reduced fatigue, falling asleep faster and not waking up as much. Researchers concluded that in addition to improving sleep in people with insomnia, lemborexant can reduce daytime fatigue.
利眠宁对失眠相关疲劳的影响:通俗易懂的摘要
本文是最初发表在《研究生医学》(Postgraduate Medicine)杂志上的一篇文章的摘要。Lemborexant是一种被称为双奥曲肽受体拮抗剂(通常缩写为DORA)的药物,已被批准用于治疗失眠症患者。有两项研究,一项名为 "SUNRISE-1"(研究 304),为期一个月;另一项名为 "SUNRISE-2"(研究 303),为期 12 个月。失眠症患者在白天经常会感到疲劳(或疲倦),这影响了他们的日常生活和健康,而且他们通常还患有其他也会导致疲劳的疾病。本摘要报告了一项分析,该分析考察了伦博雷沙坦是否能改善所有参与者的白天疲劳以及夜间失眠症状,以及治疗前有临床明显疲劳症状的参与者的白天疲劳和夜间失眠症状。在这两项研究中,参与者都填写了一份名为 "疲劳严重程度量表 "的调查问卷,以测量他们的疲劳程度有多严重。研究人员观察了与服用安慰剂的患者相比,接受伦博雷沙坦治疗的患者随着时间的推移疲劳程度的变化。他们还观察了一组在研究开始时报告了临床重要疲劳程度的参与者的变化。参加这些研究的人还填写了入睡时间和睡眠时间的日记。研究人员将疲劳程度的改善情况与参与者睡眠时间的变化进行了比较。总体而言,与安慰剂相比,所有研究参与者的lemborexant都能减轻白天的疲劳感。在研究开始时有明显临床疲劳感的一小部分参与者中,它也能减轻白天的疲劳感。在一年的治疗过程中,伦博雷沙坦缓解疲劳的效果依然存在。疲劳减轻、入睡更快和醒来次数减少之间也有关系。研究人员得出结论,除了改善失眠症患者的睡眠,lemborexant 还能减轻白天的疲劳。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future Neurology
Future Neurology CLINICAL NEUROLOGY-
CiteScore
2.10
自引率
0.00%
发文量
10
期刊介绍: The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信